How a Boston hospital is priming medical residents to use GPT-4; scientists react to Stanford president's resignation

A Boston hospital is training medical residents to test the limits and potential of artificial intelligence tools like GPT-4 in their work.

July 20, 2023 Check out STAT+

Sponsored By

Brittany Trang/STAT Preparation over panic: How a Boston hospital is priming medical residents for an era of AI medicine A Boston hospital is training medical residents to test the limits and potential of artificial intelligence tools like GPT-4 in their work. By Brittany Trang and Katie Palmer STAT+ | Damages from tornado at Pfizer plant could compound challenges of drug shortages The damages from a tornado that hit a Pfizer plant in North Carolina could compound the challenges of drug shortages. By Ed Silverman Critics and defenders weigh in on Stanford president's resignation after research investigation Marc Tessier-Lavigne's departure was a positive example of scientific accountability for some; others were disappointed in the investigation. By Jonathan Wosen and Annalisa Merelli FABRICE COFFRINI/AFP via Getty Images A Q&A with Gavi's Seth Berkley on vaccines, Covid, and challenges ahead Berkley, who will step down from his post at the start of August, has headed the Geneva-based organization for the past dozen years. By Helen Branswell Mass. General totes up its waste in a move to tackle climate change At Massachusetts General Hospital, a waste "audit" conducted by two doctors collected almost 18 pounds per patient, per day. By Rachel Layne STAT+ | Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change Medicare pays so little for pricey CAR-T cancer drugs that hospitals sometimes lose money providing them. But that could soon change. By John Wilkerson Sammy Kimball for STAT BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford Neil Kumar, CEO of BridgeBio, joins us this episode to talk about how his small company came to develop what could be a big drug. By Damian Garde and Meg Tirrell and Adam Feuerstein STAT+ | Vir antibody drug aimed at influenza A fails in clinical trial Vir's results are a setback in efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser